​

Axsome Therapeutics (AXSM) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

AXSM Stock Forecast

Axsome Therapeutics stock forecast is as follows: an average price target of $133.00 (represents a 46.59% upside from AXSM’s last price of $90.73) and a rating consensus of 'Buy', based on 14 wall street analysts offering a 1-year stock forecast.

AXSM Price Target

The average price target for Axsome Therapeutics (AXSM) is $133.00 based on 1-year price targets from 14 Wall Street analysts in the past 3 months, with a price target range of $180.00 to $106.00. This represents a potential 46.59% upside from AXSM's last price of $90.73.

AXSM Analyst Ratings

Buy

According to 14 Wall Street analysts, Axsome Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for AXSM stock is 0 'Strong Buy' (0.00%), 13 'Buy' (92.86%), 1 'Hold' (7.14%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Axsome Therapeutics Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 12, 2024Yatin SunejaGuggenheim$135.00$99.4935.69%48.79%
Sep 11, 2024Graig SuvannavejhMizuho Securities$106.00$90.5817.03%16.83%
Sep 03, 2024Cerena ChenWells Fargo$140.00$88.8657.55%54.30%
Aug 06, 2024Raghuram SelvarajuH.C. Wainwright$180.00$83.21116.32%98.39%
Aug 06, 2024Jason GerberryBank of America Securities$106.00$83.9326.30%16.83%
Jul 22, 2024Leonid TimashevRBC Capital$131.00$84.8554.39%44.38%
Jun 05, 2024Leonid TimashevRBC Capital$130.00$72.2479.96%43.28%
May 28, 2024David AmsellemPiper Sandler$115.00$75.1952.95%26.75%
Apr 29, 2024Vikram PurohitMorgan Stanley$115.00$74.1455.11%26.75%
Mar 28, 2024Graig SuvannavejhMizuho Securities$109.00$79.1737.68%20.14%
Mar 18, 2024Joel BeattyRobert W. Baird$108.00$72.5448.88%19.03%
Jan 05, 2023Piper Sandler$75.00$73.342.26%-17.34%
Dec 23, 2022Robert HazlettBTIG$98.00$75.1330.44%8.01%
Nov 29, 2022Morgan Stanley$86.00$74.9514.74%-5.21%
Nov 29, 2022Leerink Partners$85.00$74.7413.73%-6.32%
Nov 11, 2022Guggenheim$80.00$55.4844.18%-11.83%
Aug 19, 2022Joon LeeTruist Financial$150.00$59.03154.11%65.33%
May 03, 2022Mizuho Securities$49.00$34.0443.95%-45.99%
Apr 27, 2022Morgan Stanley$27.00$30.59-11.74%-70.24%
Mar 01, 2022Joon LeeTruist Financial$90.00$30.98190.51%-0.80%
Aug 10, 2021Ashwani VermaBank of America Securities$25.00$23.785.13%-72.45%

The latest Axsome Therapeutics stock forecast, released on Nov 12, 2024 by Yatin Suneja from Guggenheim, set a price target of $135.00, which represents a 35.69% increase from the stock price at the time of the forecast ($99.49), and a 48.79% increase from AXSM last price ($90.73).

Axsome Therapeutics Price Target by Period

1M3M12M
# Anlaysts-111
Avg Price Target-$135.00$125.00
Last Closing Price$90.73$90.73$90.73
Upside/Downside-100.00%48.79%37.77%

In the current month, the average price target of Axsome Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Axsome Therapeutics's last price of $90.73. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Nov 12, 2024GuggenheimBuyBuyHold
Oct 04, 2024Wells FargoBuyBuyHold
Oct 04, 2024UBSUnderperformUnderperformHold
Sep 16, 2024Cowen & Co.BuyBuyHold
Sep 09, 2024UBSUnderperformUnderperformHold
Sep 09, 2024Wells FargoBuyBuyHold
Sep 05, 2024H.C. WainwrightBuyBuyHold
Sep 03, 2024Wells FargoBuyOverweightInitialise
Aug 23, 2024Morgan StanleyOverweightOverweightHold
Aug 22, 2024RBC CapitalUnderperformUnderperformHold
Aug 22, 2024UBSBuyBuyHold
Aug 06, 2024H.C. WainwrightBuyBuyHold
Aug 06, 2024Bank of America SecuritiesNeutralBuyUpgrade
Aug 05, 2024NeedhamUnderperformUnderperformHold
Jul 22, 2024RBC CapitalOutperformOutperformHold
Jul 22, 2024NeedhamBuyInitialise
Jul 18, 2024RBC CapitalBuyBuyHold
Jul 18, 2024Morgan StanleyUnderperformUnderperformHold
Jun 11, 2024CitigroupBuyBuyHold
Jun 11, 2024GuggenheimBuyBuyHold
Jun 05, 2024Morgan StanleyUnderperformUnderperformHold
Jun 05, 2024RBC CapitalBuyBuyHold
Jun 05, 2024RBC CapitalOutperformOutperformHold
May 28, 2024Piper SandlerOverweightOverweightHold
May 06, 2024CitigroupBuyBuyHold
Apr 29, 2024UBSBuyBuyHold
Apr 29, 2024RBC CapitalUnderperformUnderperformHold
Apr 29, 2024Morgan StanleyEqual-WeightOverweightUpgrade
Mar 26, 2024CitigroupBuyBuyHold
Mar 19, 2024RBC CapitalUnderperformUnderperformHold
Mar 19, 2024UBSBuyBuyHold
Feb 27, 2024RBC CapitalUnderperformUnderperformHold
Feb 27, 2024UBSBuyBuyHold
Feb 06, 2024UBSBuyBuyHold
Feb 06, 2024RBC CapitalUnderperformUnderperformHold
Jan 16, 2024H.C. WainwrightUnderperformUnderperformHold
Jan 16, 2024Piper SandlerBuyBuyHold
Aug 08, 2023JefferiesBuyInitialise
Aug 08, 2023WedbushOutperformInitialise
Aug 08, 2023Cowen & Co.OutperformInitialise
Aug 08, 2023Bank of America SecuritiesNeutralUpgrade
Aug 08, 2023Piper SandlerNeutralOverweightUpgrade
Jul 17, 2023Wells FargoBuyBuyHold
May 08, 2023William BlairOutperformOutperformHold
Jan 05, 2023Piper SandlerNeutralInitialise
Dec 23, 2022BTIGBuyBuyHold
Nov 29, 2022Morgan StanleyEqual-WeightEqual-WeightHold
Nov 29, 2022SVB LeerinkOutperformOutperformHold
Nov 11, 2022GuggenheimBuyBuyHold
Apr 27, 2022Morgan StanleyEqual-WeightEqual-WeightHold
Apr 26, 2022Zacks Investment ResearchHoldDowngrade

Axsome Therapeutics's last stock rating was published by Guggenheim on Nov 12, 2024. The company gave AXSM a "Buy" rating, the same as its previous rate.

Axsome Therapeutics Financial Forecast

Axsome Therapeutics Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22
Revenue-------------$57.79M$46.70M$94.58M$24.37M$16.85M$8.82M
Avg Forecast$365.35M$312.69M$262.05M$199.78M$209.87M$165.95M$143.31M$121.47M$117.69M$98.37M$86.92M$73.29M$69.24M$54.87M$40.88M$25.47M$21.75M$16.64M$6.92M
High Forecast$394.07M$337.27M$282.64M$215.48M$226.37M$178.99M$154.58M$132.62M$123.09M$99.36M$86.92M$73.29M$70.60M$60.04M$44.09M$27.47M$23.46M$16.64M$6.92M
Low Forecast$328.65M$281.28M$235.72M$179.71M$188.79M$149.28M$128.92M$107.12M$110.30M$97.38M$86.92M$73.29M$66.51M$48.88M$36.77M$22.91M$19.57M$16.64M$6.92M
# Analysts334545271153471099888
Surprise %-------------1.05%1.14%3.71%1.12%1.01%1.27%

Axsome Therapeutics's average Quarter revenue forecast for Dec 23 based on 7 analysts is $69.24M, with a low forecast of $66.51M, and a high forecast of $70.60M. AXSM's average Quarter revenue forecast represents a 19.81% increase compared to the company's last Quarter revenue of $57.79M (Sep 23).

Axsome Therapeutics EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22
# Analysts334545271153471099888
EBITDA-------------$-62.12M$-65.06M$-4.96M$-53.70M$-40.49M$-38.77M
Avg Forecast$85.39M$73.08M$61.24M$46.69M$49.05M$38.78M$33.49M$28.39M$27.51M$22.99M$20.31M$17.13M$16.18M$12.82M$9.55M$5.95M$5.08M$4.49M$1.87M
High Forecast$92.10M$78.82M$66.06M$50.36M$52.90M$41.83M$36.13M$30.99M$28.77M$23.22M$20.31M$17.13M$16.50M$14.03M$10.30M$6.42M$5.48M$4.49M$1.87M
Low Forecast$76.81M$65.74M$55.09M$42.00M$44.12M$34.89M$30.13M$25.04M$25.78M$22.76M$20.31M$17.13M$15.54M$11.42M$8.59M$5.35M$4.57M$4.49M$1.87M
Surprise %--------------4.84%-6.81%-0.83%-10.56%-9.02%-20.77%

undefined analysts predict AXSM's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Axsome Therapeutics's previous annual EBITDA (undefined) of $NaN.

Axsome Therapeutics Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22
# Analysts334545271153471099888
Net Income-------------$-62.20M$-67.17M$-11.22M$-66.76M$-47.23M$-42.84M
Avg Forecast$108.95M$74.19M$41.06M$1.81M$13.76M$-14.91M$-28.58M$-43.98M$-46.13M$-66.60M$-62.93M$-57.99M$-56.39M$-57.93M$-58.42M$-62.77M$-54.20M$-49.96M$-47.86M
High Forecast$120.09M$81.78M$45.25M$1.99M$15.17M$-12.96M$-24.85M$-30.39M$-22.10M$-57.90M$-54.71M$-50.41M$-50.33M$-45.27M$-50.79M$-54.57M$-47.12M$-49.96M$-47.86M
Low Forecast$94.72M$64.50M$35.70M$1.57M$11.97M$-16.43M$-31.50M$-67.57M$-79.28M$-73.41M$-69.36M$-63.91M$-68.04M$-64.74M$-64.39M$-69.19M$-59.74M$-49.96M$-47.86M
Surprise %-------------1.07%1.15%0.18%1.23%0.95%0.89%

Axsome Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. AXSM's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Axsome Therapeutics SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22
# Analysts334545271153471099888
SG&A-------------$83.19M$78.94M$74.19M$61.50M$40.89M$31.16M
Avg Forecast$539.03M$461.33M$386.61M$294.74M$309.64M$244.83M$211.44M$179.21M$173.64M$145.13M$128.24M$108.13M$102.16M$80.95M$60.31M$37.58M$32.09M$24.54M$10.21M
High Forecast$581.40M$497.60M$417.00M$317.91M$333.98M$264.08M$228.06M$195.66M$181.61M$146.59M$128.24M$108.13M$104.16M$88.57M$65.05M$40.53M$34.62M$24.54M$10.21M
Low Forecast$484.88M$414.99M$347.77M$265.13M$278.53M$220.24M$190.20M$158.05M$162.73M$143.67M$128.24M$108.13M$98.12M$72.12M$54.25M$33.80M$28.87M$24.54M$10.21M
Surprise %-------------1.03%1.31%1.97%1.92%1.67%3.05%

Axsome Therapeutics's average Quarter SG&A projection for Dec 23 is $102.16M, based on 7 Wall Street analysts, with a range of $98.12M to $104.16M. The forecast indicates a 22.80% rise compared to AXSM last annual SG&A of $83.19M (Sep 23).

Axsome Therapeutics EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22
# Analysts334545271153471099888
EPS-------------$-1.32$-0.00$-0.26$-1.54$-1.13$-1.10
Avg Forecast$2.26$1.54$0.85$0.04$0.29$-0.31$-0.59$-0.91$-0.96$-1.38$-1.31$-1.20$-1.17$-1.20$-1.21$-1.30$-1.13$-1.05$-1.01
High Forecast$2.49$1.70$0.94$0.04$0.32$-0.27$-0.52$-0.63$-0.46$-1.20$-1.14$-1.05$-1.05$-0.94$-1.06$-1.13$-0.98$-1.05$-1.01
Low Forecast$1.97$1.34$0.74$0.03$0.25$-0.34$-0.65$-1.40$-1.65$-1.52$-1.44$-1.33$-1.41$-1.34$-1.34$-1.44$-1.24$-1.05$-1.01
Surprise %-------------1.10%0.00%0.20%1.37%1.08%1.09%

According to undefined Wall Street analysts, Axsome Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to AXSM previous annual EPS of $NaN (undefined).

Axsome Therapeutics Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
HEPAHepion Pharmaceuticals$0.52$70.0013361.54%Buy
PDSBPDS Bio$1.96$9.00359.18%Buy
TERNTerns Pharmaceuticals$6.80$18.67174.56%Buy
VKTXViking Therapeutics$46.70$97.80109.42%Buy
AMLXAmylyx Pharmaceuticals$4.28$8.2592.76%Buy
DAWNDay One Biopharmaceuticals$12.64$24.0089.87%Buy
AKROAkero Therapeutics$30.61$50.0063.35%Buy
SRPTSarepta Therapeutics$125.76$187.2048.85%Buy
ACADACADIA Pharmaceuticals$17.41$25.5046.47%Buy
AXSMAxsome Therapeutics$93.51$133.0042.23%Buy
MCRBSeres Therapeutics$0.88$1.2542.05%Buy
INCYIncyte$69.40$90.1129.84%Buy
BPMCBlueprint Medicines$96.48$122.6027.07%Buy
MDGLMadrigal Pharmaceuticals$306.08$315.753.16%Buy
TGTXTG Therapeutics$33.57$23.75-29.25%Buy

AXSM Forecast FAQ

Is Axsome Therapeutics a good buy?

Yes, according to 14 Wall Street analysts, Axsome Therapeutics (AXSM) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 13 'Buy' recommendations, accounting for 92.86% of AXSM's total ratings.

What is AXSM's price target?

Axsome Therapeutics (AXSM) average price target is $133 with a range of $106 to $180, implying a 46.59% from its last price of $90.73. The data is based on 14 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Axsome Therapeutics stock go up soon?

According to Wall Street analysts' prediction for AXSM stock, the company can go up by 46.59% (from the last price of $90.73 to the average price target of $133), up by 98.39% based on the highest stock price target, and up by 16.83% based on the lowest stock price target.

Can Axsome Therapeutics stock reach $140?

AXSM's highest twelve months analyst stock price target of $180 supports the claim that Axsome Therapeutics can reach $140 in the near future.

What are Axsome Therapeutics's analysts' financial forecasts?

Axsome Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $640.6M (high $692.56M, low $574.11M), average EBITDA is $149.71M (high $161.86M, low $134.17M), average net income is $-73.71M (high $-53.029M, low $-104M), average SG&A $945.12M (high $1.02B, low $847.01M), and average EPS is $-1.531 (high $-1.102, low $-2.151). AXSM's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $1.14B (high $1.23B, low $1.03B), average EBITDA is $266.4M (high $287.34M, low $239.64M), average net income is $226.01M (high $249.11M, low $196.49M), average SG&A $1.68B (high $1.81B, low $1.51B), and average EPS is $4.69 (high $5.17, low $4.08).

Did the AXSM's actual financial results beat the analysts' financial forecasts?

Based on Axsome Therapeutics's last annual report (Dec 2022), the company's revenue was $50.04M, beating the average analysts forecast of $45.31M by 10.44%. Apple's EBITDA was $-171M, missing the average prediction of $11.44M by -1594.12%. The company's net income was $-198M, beating the average estimation of $-152M by 30.09%. Apple's SG&A was $159.25M, beating the average forecast of $66.85M by 138.24%. Lastly, the company's EPS was $-4.86, beating the average prediction of $-3.182 by 52.73%. In terms of the last quarterly report (Sep 2023), Axsome Therapeutics's revenue was $57.79M, beating the average analysts' forecast of $54.87M by 5.33%. The company's EBITDA was $-62.12M, missing the average prediction of $12.82M by -584.43%. Axsome Therapeutics's net income was $-62.199M, beating the average estimation of $-57.927M by 7.38%. The company's SG&A was $83.19M, beating the average forecast of $80.95M by 2.76%. Lastly, the company's EPS was $-1.32, beating the average prediction of $-1.203 by 9.70%